Jist a refresher on PCYC , which I am sure most investors are hoping for a similar resolution. At the time of it’s buyout, AbbVie which purchased the company and thus 50% rights to imbruvica (other 50% was owned by JNJ) for $20 Billion, stated at time of acquisition that the drug had 60 academic/sponsored trials of imbruvica underway … imbruvica also had several FDA approvals at the time…
Geron (which owns 100% less their royalty deal), of course has 1 approval and also has about 10-20 ongoing sponsored / academic trials currently. I am sure big Pharma is following them pretty closely …
PCYC / Imbruvica
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: PCYC / Imbruvica
Just finishing my thought here... Imbruvica (as PCYC's only established drug) was valued at $40 Billion at acquisition (and both conglomerates made off handsomely from their 50% stakes). Imetelstat (as GERN's only established drug) is valued at under $1 Billion currently. It may not ever be valued at $40 Billion, but the current valuation basically assesses Imetelstat as a failure, failed launch.
The canary in the coal mine filled with smoke and mirrors imo is the academic research. When brilliant academic minds are taking interest, and devoting literally years of their careers to study the drug and it's potential, that's how we know (imo) if a newly launched drug is indeed a failure or a blockbuster, or as may be the case with Rytelo, somewhere in between. Even "in between" means around $3-5 Billion for a bio conglomerate, aka pocket change.
I'm still thinking blockbuster potential, but, let's see if the dozen or so current academic trials begins to expand.... hopefully balloon.... that and of course revenue trajectory lol. That should start it's rise, imminently.
The canary in the coal mine filled with smoke and mirrors imo is the academic research. When brilliant academic minds are taking interest, and devoting literally years of their careers to study the drug and it's potential, that's how we know (imo) if a newly launched drug is indeed a failure or a blockbuster, or as may be the case with Rytelo, somewhere in between. Even "in between" means around $3-5 Billion for a bio conglomerate, aka pocket change.
I'm still thinking blockbuster potential, but, let's see if the dozen or so current academic trials begins to expand.... hopefully balloon.... that and of course revenue trajectory lol. That should start it's rise, imminently.